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Phosphorylation state-dependent interaction between AKAP7δ/γ 
and phospholamban increases phospholamban phosphorylation
Marc Rigatti, Andrew V. Le, Claire Gerber, Ion I. Moraru*, and Kimberly L. Dodge-Kafka*,†
Pat and Jim Calhoun Center for Cardiovascular Research, UCONN Health, 263 Farmington Ave, 
Farmington, CT 06030, USA
The Richard D. Berlin Center for Cell Analysis & Modeling, UCONN Health, 400 Farmington Ave, 
Farmington, CT 06030, USA
Abstract
Changes in heart rate and contractility in response to sympathetic stimulation occur via activation 
of cAMP dependent protein kinase A (PKA), leading to phosphorylation of numerous substrates 
that alter Ca2+ cycling. Phosphorylation of these substrates is coordinated by A-kinase anchoring 
proteins (AKAPs), which recruit PKA to specific substrates [1]. Phosphorylation of the PKA 
substrate phospholamban (PLB) is a critical determinant of Ca2+ re-entry into the sarcoplasmic 
reticulum and is coordinated by AKAP7δ/γ [2,3]. Here, we further these findings by showing that 
phosphorylation of PLB requires interaction with AKAP7δ/γ and that this interaction occurs only 
when PLB is unphosphorylated. Additionally, we find that two mutants of PLB (R9C and Δ14), 
which are associated with dilated cardiomyopathy in humans, prevent association with AKAP7δ/γ 
and display reduced phosphorylation in vitro. This finding implicates the AKAP7δ/γ-PLB 
interaction in the pathology of the disease phenotype. Further exploration of the AKAP7δ/γ-PLB 
association demonstrated a phosphorylation state-dependence of the interaction. Computational 
modeling revealed that this mode of interaction allows for small amounts of AKAP and PKA 
(100–200nM) to regulate the phosphorylation of large quantities of PLB (50µM). Our results 
confirm that AKAP7γ/δ binding to PLB is important for phosphorylation of PLB, and describe a 
novel phosphorylation state-dependent binding mechanism that explains how phosphorylation of 
highly abundant PKA substrates can be regulated by AKAPs present at ~100–200 fold lower 
concentrations.
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1 Introduction
The heart responds to an increase in sympathetic stimulation via activation of the cAMP-
dependent protein kinase PKA, leading to phosphorylation of several key substrates. These 
substrates mediate Ca2+ entry, release, and uptake into intracellular stores. Phosphorylation 
therefore allows the heart to increase the force contraction and the rate of relaxation by 
changing the kinetics of the Ca2+ transients that underlie these physiological events. 
Importantly, several key studies have demonstrated that PKA must be compartmentalized 
with its substrate in the heart in order for phosphorylation to occur [4]. This is accomplished 
via A-kinase anchoring proteins (AKAPs), a class of scaffolding proteins that 
compartmentalize PKA with its substrates, thereby forming a microdomain of PKA activity. 
Importantly, disruption of PKA anchoring using global AKAP/PKA disrupting peptides 
greatly impacted the contractile response of the myocyte to sympathetic stimulation, 
demonstrating the importance of AKAPs for regulation of cardiac Ca2+ dynamics [5,6].
A key AKAP that plays a role in the regulation of cardiac Ca2+ dynamics is AKAP7 [7]. 
This AKAP has four splice variants (α, β, γ and δ), which display a range of molecular 
weights from 18 to 50 kDa [8]. AKAP7δ/γ plays an important role in the rate of relaxation 
of the heart via mediating the phosphorylation of the cardiac protein phospholamban (PLB) 
[3]. In its unphosphorylated state, PLB binds to the Sarcoplasmic Reticulum Ca2+-ATPase 
(SERCA2) pump and decreases pump action, thus providing a rate-limiting step in the 
cardiac contraction/relaxation cycle. In contrast, phosphorylation of PLB disrupts the PLB/
SERCA2 interaction, thereby accelerating Ca2+ re-uptake into cardiac stores and allowing 
for an increase in the rate of relaxation. Importantly, peptide-based disruption of the 
AKAP7δ/PLB interaction in the rat myocyte significantly attenuated the sympathetic-
promoted phosphorylation of the protein and the increase in Ca2+ re-uptake associated with 
stimulation [3]. It is important to note that AKAP7δ is replaced by AKAP7γ in the human 
and mouse myocyte [9]. Hence, it has been suggested that this interaction could be used as a 
potential drug target in heart failure patients [10].
A number of AKAP7δ/γ binding partners with the capacity to influence PLB 
phosphorylation have been identified including protein kinase C (PKC), protein 
phosphatase-1, inhibitor-1 (I-1), and phosphodiesterase 3A (PDE3A) [11–13]. This evidence 
provides us with the key elements of the AKAP7δ/γ signaling microdomain, which may 
control PLB phosphorylation. However, one particularly critical question exists: how does a 
low abundance protein like AKAP7δ/γ regulate phosphorylation of a very high abundance 
protein like PLB? This question was eloquently posed by Don Bers in his 2002 review of 
cardiac-excitation contraction coupling, commenting “…it is less clear how targeting would 
practically work for phospholamban and troponin I phosphorylation (as compared with ICa 
or Ryanodine Receptor). This would require very high amounts of the various anchoring 
and signaling proteins because troponin I and phospholamban are present at 50µM or 
higher concentrations and are dispersed widely in the cell [14].”
The implied assumption of AKAP microdomain signaling is that AKAPs remain bound to 
their respective PKA substrates regardless of the state of the complex. If true, such a 
mechanism would require an abundance of both AKAP and its binding partners that is 
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similar to that of the PKA substrates – but the cellular concentration of PKA is not nearly as 
high as PLB, nor are the concentrations of AKAP7δ/γ or its other binding partners (Protein 
phosphatase 1, Inhibitor-1 and Phosphodiesterase 3A) [12,15–18]. However, it is clear that 
the AKAP plays an important role in the phosphorylation of PLB [19]. Here, we confirm 
that binding of PKA to AKAP7δ/γ is required for PLB phosphorylation and that deletion of 
the PKA binding domain on the AKAP7 results in a significant reduction in PLB 
phosphorylation. Importantly, several human mutants of PLB, which are known to exhibit 
decreased phosphorylation and are associated with dilated cardiomyopathy, do not interact 
with AKAP7δ/γ, further suggesting that the PLB/AKAP7δ/γ is necessary for 
phosphorylation. Therefore, the question remains: how are these AKAP-binding 
requirements compatible with the efficient phosphorylation of large amounts of PLB? We 
hypothesized that this could be explained by our newly observed phosphorylation state-
dependent binding of AKAP7δ/γ to PLB. Here, we show that the high affinity association 
between AKAP7δ/γ and PLB is lost upon phosphorylation of PLB. A computation model of 
the detailed biochemical kinetics of the pathway showed that if state-dependent binding is 
included in the reaction network, phosphorylation of high concentrations of PLB is possible 
at low concentrations of both AKAP7γ and PKA, consistent with the observed results [19]. 
Importantly, our experimental findings and kinetic analysis provide a mechanistic 
hypothesis of AKAP7δ/γ complex signaling in cardiac myocytes that reconciles the problem 
with disparity of complex component concentrations.
2 Experimental Methods
2.1 Antibodies
The following primary antibodies were used for immunoblotting: mouse monoclonal 
Phospholamban (Millipore; 1:1000 dilution), polyclonal phosphor-phospholaman serine 16 
(Millipore; 1:500), mouse monoclonal GFP (Santa Cruz Biotechnology; 1:500 dilution), 
polyclonal mCherry (Thermo Scientific Pierce; 1:3000 dilution), monoclonal PKA RIIα 
subunit (Santa Cruz Biotechnology; 1:500).
Immunoprecipitations were carried out using the following antibodies: polyclonal AKAP7 
(Sigma; 5 µg), mouse monoclonal GFP (Santa Cruz Biotechnology; 5 µg), mouse 
monoclonal Phospholamban (Millipore; 3 µg)
2.2 Expression constructs
The human phospholamban construct was obtained Origene and amended with EcoRI/
BamHI restriction sites using PCR, and subcloned into the peGFP-N1 vector. Mutant 
phospholamban constructions were made by site directed mutagenesis.
2.3 Cell Transfection and Immunoprecipitation
HEK293 cells were transfected at 50–70% confluency in 60 mm plates using the calcium 
phosphate method with 6 µg of each plasmid DNA. Cells were treated with various drugs for 
the time given, and cell lysate was collected in 0.5 ml HSE buffer (HEPES, pH 7.4, 150 mM 
NaCl, 5 mM EDTA, 1% Triton X-100 and protease inhibitors). Supernatants were incubated 
overnight at 4°C with the indicated antibody and 15 µl of prewashed protein A-or G-agarose. 
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Following extensive washing, captured proteins were solubilized in 2X sample buffer and 
analyzed by immunoblot.
Rat heart extract was prepared as previously described [20,21]. Immunoprecipitating 
antibodies were added to 500 µl of extract along with 13 µl protein agarose. After an 
overnight incubation followed by extensive washing, captured proteins were analyzed by 
immunoblot.
2.4 In vitro Phospholamban phosphorylation assays
Various PLB peptides (1 µg) were incubated in kinase buffer (50 mM Tris-HCL pH 7.5, 5 
mM MgCl2) containing 100 µM ATP, 5 µM [γ−32]ATP and 800 units of purified PKA 
catalytic subunit (NEB). After a 15 minute incubation at 30°C, the reaction mixture was 
spotted onto phosphocellulose strips and washed five times in 75 mM phosphoric acid. 
Filters were air dried and counted.
2.5 Rat neonatal myocyte culture
Myocytes were prepared from 2 day old Sprague-Dawley rats, as previously described. Cell 
were plated in Dulbecco’s Modified Eagle medium (DMEM)with 17% Media 199, 1% 
penicillin/streptomycin solution, 10% horse serum and 5% fetal bovine serum (FBS) at 
125,ooo per cm2. After an overnight incubation in plating medium, the myocytes were 
maintained in culture for up to one week in maintenance medium (79%DMEM, 20% Media 
199, and antibiotic). Cells were stimulated with the various drugs as described.
2.6 Surface Plasmon Resonance
SPR analysis was performed using a BIAcore T100. Biotinylated-Phospholamban peptide 
(Chi Scientific) was covalently immobilized using NHS (N-hydroxysuccinamide) and EDC 
[1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide] (Biacore amine coupling kit) to the 
surface of a sensor chip (BIAcore type CM5). The amount of ligand bound (in resonance 
units, RUs) was 300 RU. AKAP7γ protein analyte was diluted at increasing concentrations 
(12.50–200 nM) in HBS buffer (10 mM HEPES (pH 7.4), 150 mM NaCl, and 0.005% 
Surfactant P20) and injected over the sensor surface at a flow rate of 30 µL/min for 300 
seconds. Post injection phase, dissociation was monitored in HBS buffer for 300 seconds at 
the same flow rate. The surface was regenerated between injections using 10 mM NaCl at a 
flow rate of 50 µL/min for 30 seconds. Sensorgrams were all processed by BIAcore T100 
evaluation software.
2.7 GST-RII pulldown assay
Beads charged with RIIα-GST fusion protein were incubated with isolated cell lysate 
transfected as described above. After an overnight incubation at 4C with shaking, beads 
were washed extensively and captured proteins were solubilized in 2X sample buffer and 
analyzed by immunoblot.
2.8 Computational Modeling of the AKAP7/Phospholamban complex
An ordinary differential equation (ODE) model of PLB phosphorylation by AKAP7δ/γ 
bound PKA was implemented using the Virtual Cell modeling software. The reaction 
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network is composed two basic modules; 1) cAMP production and PKA activation and 2) 
AKAP7δ/γ binding and phosphorylation of PLB with a total of 18 species and 14 reactions 
(Table 1, Fig S1). Activation of AC via association with Gs in module 1 results in the 
production of cAMP that binds PKA (R2C2) resulting in sequential dissociation of each of 
two catalytic subunits (C). Free C is able to phosphorylate Gs within the GsAc complex 
resulting in the inhibition of cAMP production and, in conjunction with the activity of PDE, 
the return of cAMP levels to baseline. Due to the high affinity interaction of cAMP with the 
PKA regulatory subunit (R), C does not reassociate with R to form PKA (R2C2) following 
cAMP stimulation. In order to return PKA activity to baseline following stimulation we 
allowed cAMP bound R (R2_cAMP) to be stripped of cAMP by PDE (reference). In the 
second module of the reaction network PLB associates with AKAP to form a complex 
(AKAP_PLB) followed by phosphorylation of PLB (AKAP_pPLB). All AKAP is bound to 
PKA derived from the total pool of PKA in module 1. Since AKAP bound PKA activity 
represents only a fraction of the total PKA activity, the total AKAP-PKA activity is defined 
by the following equation:
where E represents the total amount of enzyme (active PKA) from the AKAP bound pool of 
PKA that is available to participate in the phosphorylation of PLB which, is defined by 
standard Michaelis-Menten kinetics:
To simulate the difference between phosphorylation state-dependent (AKAP does not bind 
pPLB) and phosphorylation state-independent (AKAP binds both PLB and pPLB) the 
reverse rate for the interaction of AKAP and pPLB was modulated so that AKAP bound 
pPLB with either equal or lower affinity than PLB.
For state-independent binding, the affinity of AKAP for pPLB is the same as in the non-
phosphorylated state and for state-dependent binding the forward rate was increased. For 
state-dependent binding to PLB the reverse rate of the AKAP-pPLB interaction was 
increased by a factor of 1000, changing the affinity from 13.3nm to 13.3µM. The model is 
available in the public biomodels folder of the Virtual Cell software.
3 Results
3.1 AKAP7γ directly binds to phospholamban
Due to conflicting evidence demonstrating the importance of AKAP7δ/γ for phospholamban 
(PLB) phosphorylation [3,19], we investigated the dynamics of AKAP7 binding to PLB as a 
possible regulatory function of phosphorylation. To begin with, we confirmed previous 
findings that AKAP7δ/γ binds directly to PLB [3]. As shown in Figure 1A, PLB co-
immunoprecipitated with AKAP7 from isolated rat heart extract, but not with control IgG, 
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demonstrating that these two proteins form a complex in cardiac myocytes. Next, we 
investigated if this interaction was specific for the cardiac myocyte, or if association could 
be detected in a heterologous system. HEK293 cells were transfected with plasmids 
expressing mCherry-AKAP7γ in the presence and absence of GFP-phospholabman. GFP 
was immunoprecipitated and the association of AKAP7γ was determined by Western blot 
analysis (Figure 1B). Importantly, co-precipitation of mCherry-AKAP7γ was only seen in 
cells expressing GFP-PLB, demonstrating the specificity of the interaction. To further these 
findings and examine the kinetic properties of the interaction, we performed surface 
plasmon resonance (SPR). As the domain on phosholamban for binding to AKAP7 is 
maintained in the first 21 amino acids, we immobilized a peptide mimicking this domain on 
a CM5 sensor chip. Varying concentrations of purified AKAP7γ were used to determine the 
dynamics of the interaction. As shown in Figure 1C, we confirmed a direct interaction 
between phospholamban and AKAP7γ with an affinity of 13.3nM. Analysis of the fit of the 
interaction suggests one site of interaction. Taken together, these data confirm the original 
observation demonstrating a direct association of AKAP7 with phospholamban that can be 
isolated from cardiac myocytes.
3.2 PKA bound to AKAP7δ/γ is responsible for phosphorylation of phospholamban
The primary purpose of AKAPs is to co-localize PKA and its substrate via formation of a 
multi-component signaling complex, resulting in enhanced substrate phosphorylation. 
Therefore, we next examined the necessity of PKA binding to AKAP7δ/γ for PLB 
phosphorylation. To investigate this association in an endogenous tissue, PLB was 
immunoprecipitated from rat heart lysate, and association with PKA was determined in the 
presence or absence of the AKAP/PKA disrupting peptide AKAP-IS (Figure 2A) [22]. 
Disruption of PKA anchoring using the AKAP-IS peptide decreased association of the PKA 
RII subunit with PLB. Importantly, incubation of a control peptide did not significantly 
affect PKA/PLB interaction, demonstrating that PKA associates with PLB via interaction 
with AKAP. To determine the role of AKAP7γ in mediating this association, HEK293 cells 
were transfected with GFP-PLB and either wild-type mCherry-AKAP7γ, or one lacking the 
PKA binding domain (mCherry-ΔPKA-AKAP7γ). Lysate isolated from these cells was 
subjected to pulldown analysis using GST-tagged PKA RIIα subunit. This is a common 
technique used to isolate AKAP complexes from various tissues, as the RII subunit will 
pulldown the AKAP and all AKAP-associated proteins [12,23]. As shown in Figure 2B, 
GFP-PLB only associated with the PKA subunit in the presence of full-length AKAP7γ. 
However, when the PKA binding domain was deleted from the AKAP, GST-RIIα could no 
longer pulldown PLB, demonstrating the importance of PKA anchoring to AKAP7γ. Taken 
together, these results implicate AKAP7γ for linking the kinase to the PLB complex.
Next, we investigated the functional significance of this interaction for regulation of PLB 
phosphorylation. We first performed analogous experiments to those outlined in Figure 2B, 
and looked at the role of AKAP7γ-bound PKA on PLB phosphorylation. As shown in 
Figure 2C, expression of the anchoring protein dramatically heightened PLB 
phosphorylation. However, when the PKA binding domain was deleted from the AKAP, this 
enhancement was lost, suggesting that the kinase must be attached to the AKAP for this 
effect.
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3.3 Described human mutations of phospholamban contained in the AKAP7δ/γ binding 
domain decrease complex formation, thereby reducing phosphorylation
Multiple mutations of PLB have been identified and linked to familial dilated 
cardiomyopathy. At least two of these mutations are found in the AKAP7δ/γ binding 
domain, suggesting these mutation may affect the ability of PLB to bind to the AKAP 
(Schematic diagram shown in Fig 3A). First, mutation of Arginine 9 to Cystine (PLB-R9C) 
displayed a dose-dependent inhibition of SERCA2a and significantly decreased phospho-
PLB [24]. The other is deletion of Arginine 14 (PLB-Δ14). This mutation exhibited super-
inhibition of SERCA2a activity, correlating with decreased PLB phosphorylation [25]. To 
test the importance of AKAP7δ/γ binding to PLB for the phosphorylation of PLB, we 
utilized these mutations to block the association. To begin, we examine the strength of 
interaction between AKAP7γ and these mutations using surface plasmon resonance (SPR). 
Peptides mimicking the first 21 amino acids of wild-type PLB, or ones containing the 
defined mutations (PLB-R9C and PLB-Δ14) were immobilized on a CM5 sensor chip, and 
the changes in the kinetic strength of the interaction was determined using varying 
concentrations of purified AKAP7γ flown over the chip. As shown in Figure 3B, these 
mutations dramatically affected the ability of the AKAP to bind to PLB, as the affinity of 
these two mutants for AKAP7γ are below the limit of detection.
Our SPR data suggest that mutation of the AKAP7δ/γ binding domain on PLB reduces the 
interaction with the AKAP. We therefore investigated if these mutations affected the ability 
of the complex to form in a cellular environment. AKAP7γ was coexpressed in HEK293 
with wild-type PLB-GFP, or one of the mutated isoforms (PLB-R9C-GFP or PLB-Δ14-
GFP). The PLB-GFP complex was isolated and association of AKAP7γ-mCherry was 
determined by Western Blot. As shown in Figure 3C, both mutations significantly decreased 
the co-precipitation of AKAP7γ, suggesting that a decrease in the AKAP7γ binding affinity 
measured in these mutants results in decreased association of AKAP7 with the protein in a 
cellular context.
Importantly, the decrease in complex formation seen with the PLB mutants should reduce 
the concentration of PKA found in the PLB complex. To test this hypothesis, AKAP7γ was 
coexpressed in HEK293 with wild-type PLB-GFP, or one of the mutated isoforms (PLB-
R9C-GFP or PLB-Δ14-GFP). Cell lysate was subjected to GST-RII pulldown, and 
association of GFP-PLB was measured. In confirmation of our findings, wild-type PLB 
associates with the PKA subunit when co-expressed with AKAP7γ (Figure 3D). However, 
both PLB mutations showed decreased association with the GST-RII, suggesting mutation 
of PLB in the AKAP7δ/γ binding domain decreases complex formation and reduces PKA 
association with PLB.
As our hypothesis states that AKAP7δ/γ anchored PKA mediates the phosphorylation of 
PLB, the decrease in complex formation seen with the mutated isoforms of PLB should 
therefore result in a decrease in phosphorylation of the protein. To test this hypothesis, 
AKAP7γ was coexpressed in HEK293 with wild-type PLB-GFP, or one of the mutated 
isoforms (PLB-R9C-GFP or PLB-Δ14-GFP). Cells were stimulated with 100 nM 
Isoproterenol for 5 minutes, and phosphorylation of PLB was determined by Western Blot 
analysis (Figure 3E). In collaboration with those results seen in both transgenic and human 
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patients [24,25], less phosphorylation was seen with the mutated isoforms of PLB. This 
finding correlates with the decreased PKA association within the mutant complexes due to 
deceased affinities for AKAP7, suggesting that one mechanism for the attenuation of 
phosphorylation of the mutant PLB isoforms is a significant decrease in the localization of 
the kinase to the complex. However, it is plausible that this effect may result from a 
decreased ability of these mutated isoforms to be phosphorylated by the kinase and not a 
disruption in the localization of the kinase to the PLB complex. To test this, peptides 
mimicking the first 21 amino acids of wild-type PLB, PLB-R9C or PLB-Δ14 were subjected 
to an in vitro kinase assay. As shown in Figure 3F, all peptides were able to be 
phosphorylated by the kinase to a similar extent, suggesting the decrease in phosphorylation 
of the mutated PLB isoforms seen in the exogenous system is not due to a lack of ability of 
the kinase to phosphorylate the mutated isoforms. Taken together, the data shown in Figure 
3 supports the hypothesis that by linking the kinase to its substrate PLB, AKAP7δ/γ 
mediates phosphorylation of PLB.
3.4 Phosphorylation of phospholamban decreases the affinity for AKAP7δ/γ binding
Contained in the AKAP7δ/γ binding domain on PLB is the PKA phosphorylation site. We 
therefore proposed that phosphorylation of PLB would decrease the ability of the AKAP to 
interact with the protein. To test this hypothesis, we began by defining the change in affinity 
between phosphorylated PLB and non-phosphorylated PLB using SPR. We immobilized a 
peptide mimicking the first 21 amino acids of either wild-type PLB, or one that is 
permanently phosphorylated at Serine 16 to a CM5 sensor chip, and then determined the 
kinetic strength of the two interactions using varying concentrations of purified AKAP7γ. 
As shown in Figure 4A, when phosphorylated, the affinity of AKAP7γ and PLB is below 
the limit of detection, suggesting a low affinity binding. To confirm this finding in a cellular 
context, HEK293 cells were transfected with plasmids expressing mCherry-AKAP7γ and 
GFP-PLB. After a 15 minute stimulation with 100 nM Isoproterenol, GFP was 
immunoprecipitated and the association of AKAP7γ was determined by Western blot 
analysis (Figure 4B). Importantly, co-precipitation of mCherry-AKAP7γ was dramatically 
decreased under conditions that result in phosphorylation of PLB. These findings were 
confirmed in an endogenous setting. Rat neonatal myocytes were stimulated with 10 µM 
Isoproterenol for 15 minutes. Phospholamban was immunoprecipitated and association with 
the AKAP was determined by Western Blot. Taken together, these findings suggest that the 
AKAP7δ/γ interaction with PLB is dispersed upon activation of PKA and phosphorylation 
of PLB.
3.5 Phosphorylation state specific binding of AKAP7δ/γ increases phospholamban 
phosphorylation
Our finding that the AKAP7δ/γ-PLB interaction is phosphorylation state specific is 
interesting given that the purpose of this interaction is to direct PKA phosphorylation to 
PLB. Such state selective binding suggests that AKAP7δ/γ likely binds, phosphorylates, and 
then unbinds PLB in a dynamic process with the potential to increase PLB phosphorylation 
in comparison to remaining bound regardless of phosphorylation state.
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To investigate the potential consequence of state selective binding of AKAP7δ/γ to PLB, we 
created an ordinary differential equation model that simulates phosphorylation of PLB by 
AKAP7δ/γ bound PKA at baseline steady state and during cAMP stimulation. For all 
iterations of the model parameters, the simulation was run for 15000s prior to initiating our 
stimulation protocol, thus ensuring that all species reach a baseline steady state. At baseline 
steady state, the level of cAMP is 244nm and 2.4% of the total PKA is in an active state. 
Following initiation of our stimulation protocol, the levels of cAMP rise to 5.6µM activating 
94.1% of the total PKA in 90s and decaying back to baseline in roughly 500–600s (Figure 
5A). To test the effect of state specific binding, we compared the levels of phospho-PLB 
with either equal affinity of AKAP for PLB and phospho-PLB (state-independent), or 1000-
fold lower affinity for pPLB (state-dependent). We tested AKAP concentrations ranging 
from 1–250nM for both state-independent binding and state-dependent binding. 
Unpublished analysis from our lab and others suggest that the level of AKAP7δ/γ present in 
cardiac myocytes is roughly 100nm. The total amount of PLB present in these simulations is 
50µM [14]. In the range of AKAP concentrations tested, state-independent binding of 
AKAP to PLB provides minimal capacity for PLB phosphorylation, with very low levels of 
phosphorylation at baseline and minimal response to stimulation (Figure 5B). We quantified 
the response to stimulation by calculating the dynamic range, defined as the change in 
concentration of phospho-PLB from baseline to maximum, divided by the total 
concentration of PLB. The dynamic range for state-independent binding ranges from 0.01% 
to 0.17% (Figure 5C). State-dependent binding of AKAP to PLB however, allows for 
maintenance of low baseline levels of PLB phosphorylation and dramatic responses to 
stimulation (Figure 5B). With state-dependent binding, the dynamic range varies from 
0.05% to 42.3% (Figure 5D). It is important to note that while the primary determinants of 
the dynamic range of PLB phosphorylation are the affinity of AKAP for phospho-PLB and 
the AKAP concentration, the dynamic range is also modified significantly by baseline 
cAMP concentration and the amount of phosphatase present in the system. Higher baseline 
levels of cAMP (622nm) contribute to increased baseline activity of PKA and hence higher 
levels of phospho-PLB (Figures 6A and 6B). With the same level of stimulation, this results 
in a decreased dynamic range (Figure 6C). Additionally, it was noted that at higher baseline 
cAMP levels, increasing the AKAP concentration past 0.15µM resulted in dramatic 
increases in baseline phospho-PLB. While this threshold effect of AKAP concentration on 
baseline phospho-PLB will occur in the simulations with lower baseline cAMP levels, it 
requires higher concentrations AKAP than we would expect to see in vivo. We determined 
that this is primarily due to a shift in the balance of PKA and phosphatase activity. 
Increasing the amount of phosphatase in the simulations allowed for maintenance of lower 
baseline phospho-PLB levels for AKAP concentrations at the top of our range, and slightly 
reduced maximal phospho-PLB for all AKAP concentrations. This resulted in a reduced 
dynamic range at lower AKAP concentrations, yet increased the dynamic range at higher 
AKAP concentrations in comparison to simulations with a lower phosphatase concentration 
(Figure 6D). The model demonstrates that phosphorylation state-dependent binding of 
AKAP7δ/γ to PLB could allow low concentrations of AKAP7γ to phosphorylate much 
higher concentrations of PLB. Additionally, the data suggests that the significant increase in 
dynamic range seen with state-dependent binding is stable over a range of baseline cAMP 
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and phosphatase concentrations, perhaps allowing for fine-tuning of AKAP7γ complex 
signaling.
4 Discussion
The importance of AKAP7δ/γ to PLB phosphorylation and cardiac calcium dynamics has 
recently been called into question by the work of Jones et al [19]. Their AKAP7 PKA 
binding domain knockout mouse displayed no obvious phenotype, nor any defect in PLB 
phosphorylation or Ca2+ handling in response to sympathetic stimulation. Hence, the authors 
suggest that AKAP7 is not responsible for anchoring PKA to PLB, and suggest that another 
AKAP likely performs this function. Their deletion construct is expected to ablate only the 
PKA and Cav1.2 binding domains of all AKAP7 isoforms, although no effect on L-type 
calcium current were seen. It is concerning that the authors did not demonstrate that the 
truncated protein products to not associate with PKA. Additionally, it is noteworthy that 
previous work by this group found that complete ablation of AKAP5 in mice does not show 
an obvious phenotype, while specific ablation of the PKA binding domain does [26]. It is 
possible that deletion of exon 7 behaves more like a full length AKAP7-knockout, which is 
consistent with the lack of detection of all isoforms of the AKAP in this model. 
Additionally, if a truncated version of AKAP7δ/γ is still expressed in the mouse, it would 
still bind all the other components of the complex and perhaps the balance of 
phosphorylation to dephosphorylation is changed. Further investigation of this mouse model 
is warranted before concluding that AKAP7δ/γ anchoring to PKA is not important.
However, the data shown here clearly demonstrates the role of AKAP7δ/γ in mediating 
phosphorylation of PLB. AKAP7δ/γ was first identified as the AKAP that directs PKA 
mediated phosphorylation of PLB by Lygren et al in 2007. This work showed that disruption 
of the AKAP7δ-PKA interaction results in a reduction in PLB phosphorylation by 
approximately 50% and that this has a significant effect on Ca2+ dynamics [3]. Our work 
confirms this finding by showing that disruption of PKA binding to the complex, or 
decreasing the affinity for AKAP7 and PLB reduces PKA phosphorylation of PLB. Hence, 
AKAP7δ/γ should be a key player in the calcium dynamics of the heart.
Several human PLB mutations have been discovered which are associated with dilated 
cardiomyopathy. Two PLB mutants in particular, PLB-R9C and PLB-Δ14, display hypo-
phosphorylation, yet the mechanism of the decrease in phosphorylation is unclear at present 
[24,25]. We examined the ability of these PLB mutants to associate with AKAP7γ and 
found a significant reduction in binding affinity compared to WT PLB that correlated with a 
decrease in PKA association with the complex and a reduction in phosphorylation of the 
mutant proteins when compared to wild-type PLB. Together, these findings suggest that the 
impaired interaction of these PLB mutants with AKAP7δ/γ may contribute to their hypo-
phosphorylation. Given the clinically significant phenotype associated with these mutants, 
our findings indicate that the AKAP7δ/γ-PLB interaction is critically important for 
maintaining PLB phosphorylation and normal cardiac function in humans.
Phosphorylation of PLB by PKA occurs at Serine 16, which is located within the region of 
the AKAP7δ/γ binding site. The location of this phosphorylation site suggests that it may 
Rigatti et al. Page 10
Cell Signal. Author manuscript; available in PMC 2016 March 11.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
affect AKAP7δ/γ binding to PLB. Our attempts to measure the affinity of AKAP7γ for 
phosphorylated PLB (pPLB) by SPR indicate a complete lack of binding, which was 
supported in both transfected cells and stimulated rat neonatal myocytes. This finding is 
very interesting, and suggests that the AKAP7δ/γ-PLB interaction may be very dynamic. 
Given the phosphorylation dependence of this binding interaction, AKAP7γ may work by 
essentially shuttling PKA from one PLB molecule to the next as it binds, directs 
phosphorylation, and then unbinds to find its next unphosphorylated target. This sort of 
interaction has the potential to greatly amplify PLB phosphorylation.
To confirm whether the new finding of phosphorylation state binding dependency on PLB 
phosphorylation could in fact have such an amplification effect, we created an ordinary 
differential equation model of the complex dynamics. For AKAP-PLB interactions that are 
phosphorylation state-independent, the ability to achieve complete PLB phosphorylation 
would require at least an equimolar ratio of AKAP to PLB, since each PLB molecule would 
need an associated AKAP-PKA complex. In the range of AKAP concentrations tested, our 
model suggests that state-independent binding of AKAP to PLB cannot achieve levels of 
PLB phosphorylation that would allow for effective modulation of SERCA2a activity. 
Furthermore, the results suggested that state-independent binding would be insensitive to 
stimulation given that the dynamic range of phosphorylation with the maximum amount of 
AKAP tested is only ~0.2% of the total PLB concentration. However, state-dependent 
binding of AKAP to PLB enables small amounts of AKAP7γ to direct phosphorylation of 
much larger amounts of PLB. While the concentration of PLB is suggested to be 50µM or 
greater in cardiac myoctes, only 10–20% of the total PLB is in the monomeric form that can 
interact with and inhibit SERCA2a [2,14]. Our simulations show that at physiologically 
relevant concentrations of AKAP7δ/γ a dynamic range of PLB phosphorylation can be 
achieved such that complete phosphorylation of monomeric PLB is possible. Thus, 
phosphorylation state-specific binding could explain the ability of low abundance proteins 
such as AKAP7γ to regulate phosphorylation of high abundance proteins like PLB and 
troponin.
Data from our model also highlights the importance of the balance between AC and PDE 
activity, as well as PKA and phosphatase activity. The level of cAMP present in a given 
AKAP domain clearly defines the maximum dynamic range possible, as increased baseline 
cAMP results in higher baseline PKA activity resulting in a narrowed dynamic range of 
phosphorylation. While the increased baseline phosphorylation may be tempered by 
increased phosphatase activity, this too results in a slight decrease in the dynamic range of 
phosphorylation. Importantly, the significant increase in dynamic range seen with state-
dependent binding, in comparison to state-independent binding, still exists with variation in 
baseline cAMP and phosphatase concentration.
This also raises a particularly intriguing hypothesis that such a mechanism may allow the 
cell to adapt to fluctuations in baseline cAMP concentration. As cAMP concentrations rise, 
additional phosphatase could restore baseline levels of phosphorylated substrate while still 
allowing for a great enough dynamic range to provide a detectable signal. This important 
role of phosphatase in the dynamic of PLB phosphorylation is consistent with several 
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published results demonstrating the importance of phosphatase inhibition for PLB 
phosphorylation, lending further credence to these findings [27–29].
6 Conclusions
Our findings reaffirm the importance of AKAP7 in directing phosphorylation of PLB and 
present a novel mechanism that can explain the decrease in PLB phosphorylation associated 
with human PLB mutants. The state-dependent binding of AKAP7δ/γ also explains how it 
may be possible that small quantities of AKAP and PKA could regulate phosphorylation of 
large amounts of substrate, as is the case for PLB and troponin. These findings require us to 
consider that AKAP complexes in general may be much more dynamic than previously 
thought. Further investigation of the AKAP7γ-PLB complex kinetics is warranted, as well as 
careful examination of other AKAP complexes that may also exhibit similar state-dependent 
interactions.
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Highlights
• AKAP7δ/γ link PKA to phospholamban, enhancing phosphorylation of 
Phospholabman
• This interaction is disrupted in several defined human mutations
• Phosphorylation of phospholamban significantly decreases the affinity for 
AKAP7δ/γ, allowing for state-dependent binding of the AKAP
• Computational analysis of this signaling pathway suggests that state-dependent 
binding allows for small concentrations of AKAP7δ/γ and PKA to 
phosphorylated the large quantities of phospholamban seen in the cardiac 
myocyte
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Figure 1. Direct cellular interaction between AKAP7δ/γ and phospholamban
A) AKAP7 was immunoprecipitated from rat heart extract and association of PLB was 
determined by Western Blot. n=3. B) mCherry Western blot analysis of anti-GFP 
immunoprecipitates isolated from HEK-293 cells co-transfected with mCherry-AKAP7γ in 
the presence and absences of GFP-PLB (upper panels). To confirm immunoprecipitation of 
equal amounts of GFP-PLB, the nitrocellulose membranes were also probed for GFP using a 
monoclonal anti-GFP antibody (middle panel). Lower panels depict mCherry and GFP 
Western blot analysis of the input (20 µL) from each condition. n=3. C) SPR was performed 
by immobilizing a peptide containing the first 21 amino acids of PLB (150RUs) on a CM-5 
chip and measuring the response when passing over a range of concentrations (12.5–200nM) 
of AKAP7γ. Forward and reverse rates of binding and binding affinity were determined by 
fitting of the sensorgram with BIAcore T100 evaluation software.
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Figure 2. AKAP7δ/γ anchors PKA to the phospholamban complex to enhance phosphorylation
A) PLB was immunoprecipitated from rat heart lysate. Following extensive washing, the 
immunoprecipitates were incubated with the AKAP/PKA disrupting peptide AKAP-IS (10 
µM) or control peptide (10 µM) for 30 minutes while rocking. After another round of 
washing, association of the regulatory subunit of PKA was determined by Western blot. B) 
HEK-293 were transfected with GFP-PLB and either wild-type mCherry-AKAP7γ, or one 
deficient in the PKA binding domain (mCherry-ΔPKA-AKAP7γ). Isolated lysates were 
subjected to pulldown assays using bacterially purified GST-tagged PKA RII subunit 
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precharged on Glutatione-agarose; Both GFP and mCherry antibodies were used for 
detecting PLB and AKAP7γ interactions, respectively (upper panel). Protein stain of the 
nitrocellulose membrane before Western blot analysis is shown in the middle panel. Input 
from the transfected cells (20µl) is shown in the bottom panels. n=3. C) HEK-293 were 
transfected with GFP-PLB and either wild-type mCherry-AKAP7γ, or one deficient in the 
PKA binding domain (mCherry-ΔPKA-AKAP7γ). Cells were stimulated with 100 µM 
Isoproterenol for 5 minutes before cell lystate was isolated and loaded onto and SDS-PAGE 
gel. Phosphorylation of PLB at Serine 16 was determined using a phospho-specific antibody 
(upper panel). Total expression of the proteins is shown in the lower panels using both GFP 
and mCherry antibodies to detect PLB and AKAP7γ, respectively. n=3
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Figure 3. Described human mutations of phospholamban disrupt AKAP7γ binding
Schematic depiction of the mutations found in phospholamban that are found in the 
AKAP7δ/γ binding domain. B) SPR was performed by immobilizing a peptide containing 
the first 21 amino acids of either wild-type PLB, or one containing either the R9C or the Δ14 
mutation (150RUs) on a CM-5 chip and measuring the response when passing over a range 
of concentrations (12.5–200nM) of AKAP7γ. The binding affinity between the two proteins 
was determined by the BIAcore T100 evaluation software. C) mCherry Western blot 
analysis of anti-GFP immunoprecipitates isolated from HEK-293 cells co-transfected with 
mCherry-AKAP7γ and either wild-type GFP-PLB, or one of the mutated isoforms (PLB-
RC9-GFP, or PLB-Δ14-GFP, upper panels). To confirm immunoprecipitation of equal 
amounts of GFP-PLB, the nitrocellulose membrane was also probed for GFP using a 
monoclonal anti-GFP antibody (middle panel). Lower panels depict mCherry and GFP 
Western blot analysis of the input (20 µL) from each condition. n=3. D) HEK-293 were 
transfected with mCherry-AKAP7γ and either wild-type GFP-PLB, or one of the mutated 
isoforms (PLB-RC9-GFP, or PLB-Δ14-GFP, upper panels). Isolated lysates were subjected 
to pulldown assays using bacterially purified GST-tagged PKA RII subunit precharged on 
Glutatione-agarose; Both GFP and mCherry antibodies were used for detecting PLB and 
AKAP7γ interactions, respectively (upper panel). Protein stain of the nitrocellulose 
membrane before Western blot analysis is shown in the middle panel. Input from the 
transfected cells (20µl) is shown in the bottom panels. n=3. E) HEK-293 were transfected 
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with mCherry-AKAP7γ and either wild-type GFP-PLB, or one of the mutated isoforms 
(PLB-RC9-GFP, or PLB-Δ14-GFP. Cells were stimulated with 100 µM Isoproterenol for 5 
minutes before cell lystate was isolated and loaded onto and SDS-PAGE gel. 
Phosphorylation of PLB at Serine 16 was determined using a phospho-specific antibody 
(upper panel). Total expression of the proteins is shown in the lower panels using both GFP 
and mCherry antibodies to detect PLB and AKAP7γ, respectively. n=3 E) PLB peptides (1 
µg) were incubated in kinase buffer (50 mM Tris-HCL pH 7.5, 5 mM MgCl2) containing 
100 µM ATP, 5 µM [γ−32]ATP and 800 units of purified PKA catalytic subunit (NEB). After 
a 15 minute incubation at 30°C, the reaction mixture was spotted onto phosphocellulose 
strips and washed five times in 75 mM phosphoric acid. Filters were air dried and counted.
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Figure 4. Phosphorylation of PLB significantly decreases the affinity for AKAP7δ/γ
A) SPR was performed by immobilizing a peptide containing the first 21 amino acids of 
PLB that had been phosphorylated (150RUs) on a CM-5 chip and measuring the response 
when passing over a range of concentrations (12.5–200nM) of AKAP7γ. The binding 
affinity between the two proteins was determined by the BIAcore T100 evaluation software. 
B) HEK-293 were transfected with GFP-PLB and mCherry-AKAP7γ. Cells were stimulated 
with 100 µM Isoproterenol for 5 minutes and the PLB complex was isolated by 
immunoprecipitation using anti-GFP. Association of AKAP7γ was determined by Western 
blot using anti-mCherry (upper panels). To confirm immunoprecipitation of equal amounts 
of GFP-PLB, the nitrocellulose membrane was also probed for GFP using a monoclonal 
anti-GFP antibody (middle panel). Total expression of the proteins is shown in the lower 
panels using both GFP and mCherry antibodies to detect PLB and AKAP7γ, respectively. 
Phosphorylation of PLB at Serine 16 in total lysate was determined using a phospho-specific 
antibody (upper panel). n=3 C) Rat neonatal cardiac myocytes were stimulated with 10 µM 
Isoproterenol for 5 minutes and the PLB complex was isolated by immunoprecipitation. 
Association of AKAP7δ/γ was determined by Western blot (upper panel). Total expression 
of the proteins is shown in the lower panels. Phosphorylation of PLB at Serine 16 in total 
lysate was determined using a phospho-specific antibody (upper panel). n=3
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Figure 5. State dependent binding of AKAP to PLB dramatically increases PLB phosphorylation 
upon stimulation
A) cAMP concentration and PKA activity over the time-course of the simulations. All 
species in the model are at steady state prior to stimulation (t = 0s), which was achieved via 
activation of additional AC. B) pPLB concentration at baseline and maximum following 
stimulation for state independent binding of AKAP and PLB. C) pPLB concentration at 
baseline and maximum following stimulation for state dependent binding of AKAP and 
PLB. D) Dynamic range  of PLB 
phosphorylation for both state dependent and state independent binding of AKAP to PLB. 
The y-axis is on a log2 scale to enable viewing of both trends on the same graph.
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Figure 6. Increased baseline cAMP reduces dynamic range of PLB phosphorylation
A) cAMP concentration and PKA activity over the time-course of the simulations as in 
figure 5. The concentrations of AC and PDE have been adjusted to increase the baseline 
level of cAMP from 244nm to 622nm. B) pPLB concentration at baseline and maximum 
following stimulation for state dependent binding of AKAP and PLB. C) Dynamic range of 
PLB phosphorylation for state dependent phosphorylation at low (244nM) and high 
(622nM) baseline cAMP levels given AKAP concentrations ranging from 1nM to 250nM. 
D) Dynamic range of PLB phosphorylation with high baseline levels of cAMP and normal 
or increased protein phosphatase (PP).
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